Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 15;31(18):1584–1598. doi: 10.1089/neu.2009.1108

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright 2014, Mary Ann Liebert, Inc.

PMC Copyright notice

FIG. 5. — Fibronectin-positive cells respond to exogenous fibroblast growth factor-2 (FGF-2), but not to spinal cord injury (SCI). (A–D) The ratios of cell marker–expressing BrdU-positive cells to the total number of BrdU-positive cells were calculated for the injured or uninjured spinal cords after vehicle or FGF-2 injection. (A) FGF-2 administration significantly increased the ratio of fibronectin-expressing BrdU-positive cells (BrdU⁺/fibronectin⁺), regardless of injury. (B) SCI decreased the ratio of BrdU⁺/NG2⁺ cells, but FGF-2 did not. (C) Neither SCI nor FGF-2 affected the ratio of BrdU⁺/GFAP⁺ cells. (D) SCI caused a marked increase in the ratio of BrdU⁺/OX-42⁺, but the increment was attenuated by FGF-2 administration. (E) Fluorescence photomicrographs illustrate typical patterns of BrdU⁺/fibronectin⁺ (a), BrdU⁺/NG2⁺ (b), BrdU⁺/GFAP⁺ (c), and BrdU⁺/OX-42⁺ cells (d) observed in the FGF-2-treated injured spinal cord. Sections were stained for BrdU (red) or cell markers (green). Arrowheads and arrows indicate BrdU-positive cells without cell marker staining and BrdU-positive cells expressing cell marker antigen, respectively (scale bar=10 μm; *p<0.05, ***p<0.001 for the difference between the bracketed values; Sham, sham-operated animals; Vehicle, vehicle-treated uninjured animals; FGF-2, FGF-2-treated uninjured animals; SCI/Vehicle, vehicle-treated injured animals; SCI/FGF-2, FGF-2-treated injured animals; BrdU, 5-bromo-2′-deoxyuridine; GFAP, glial-fibrillary acidic protein).

FIG. 5. — Fibronectin-positive cells respond to exogenous fibroblast growth factor-2 (FGF-2), but not to spinal cord injury (SCI). (A–D) The ratios of cell marker–expressing BrdU-positive cells to the total number of BrdU-positive cells were calculated for the injured or uninjured spinal cords after vehicle or FGF-2 injection. (A) FGF-2 administration significantly increased the ratio of fibronectin-expressing BrdU-positive cells (BrdU⁺/fibronectin⁺), regardless of injury. (B) SCI decreased the ratio of BrdU⁺/NG2⁺ cells, but FGF-2 did not. (C) Neither SCI nor FGF-2 affected the ratio of BrdU⁺/GFAP⁺ cells. (D) SCI caused a marked increase in the ratio of BrdU⁺/OX-42⁺, but the increment was attenuated by FGF-2 administration. (E) Fluorescence photomicrographs illustrate typical patterns of BrdU⁺/fibronectin⁺ (a), BrdU⁺/NG2⁺ (b), BrdU⁺/GFAP⁺ (c), and BrdU⁺/OX-42⁺ cells (d) observed in the FGF-2-treated injured spinal cord. Sections were stained for BrdU (red) or cell markers (green). Arrowheads and arrows indicate BrdU-positive cells without cell marker staining and BrdU-positive cells expressing cell marker antigen, respectively (scale bar=10 μm; *p<0.05, ***p<0.001 for the difference between the bracketed values; Sham, sham-operated animals; Vehicle, vehicle-treated uninjured animals; FGF-2, FGF-2-treated uninjured animals; SCI/Vehicle, vehicle-treated injured animals; SCI/FGF-2, FGF-2-treated injured animals; BrdU, 5-bromo-2′-deoxyuridine; GFAP, glial-fibrillary acidic protein).